A Phase I/II Study of Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

• Patients must have a confirmed diagnosis of chronic lymphocytic leukemia/B-cell small lymphocytic lymphoma, any marginal zone lymphoma, follicular lymphoma, Waldenstrom’s macroglobulinemia, or mantle cell lymphoma.
• Patients must have received at least one but no more than three prior regimens of conventional chemotherapy. At least 4 weeks must have passed since prior treatment and entry into the study (6 weeks for BCNU or mitomycin C). Patients must have recovered from the side effects of all prior therapies.
• Patients must not have received any therapeutic monoclonal antibodies (such as rituximab, tositumomab, ibritumomab, or alemtuzumab) within 3 months of study entry (except for patients enrolled on the phase I portion, who may have received rituximab up to 7 days before). Patients who have been treated with monoclonal antibodies within 3 months may be enrolled if their disease continues to grow while on this therapy, as long as they have not received the treatment within 7 days of entering the study.
• Patients must be age 18 or older.

For more information and to see if you are eligible for this study, please contact Dr. John Gerecitano at 212-639-3748.